Italian Journal of Dermatology and Venereology最新文献

{"title":"Pre-exposure prophylaxis for HIV: a review for dermatovenereologists.","authors":"Luigi Pisano, Martina Turco, Nicola Pimpinelli","doi":"10.23736/S2784-8671.26.08434-3","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08434-3","url":null,"abstract":"<p><p>Human immunodeficiency virus (HIV) infection remains a significant public health issue, with 112,883 new diagnoses reported in Europe in 2023. The rise is particularly notable in Eastern Europe, where new cases increased by 20% between 2010 and 2023. Late diagnosis is a major barrier to HIV control, with nearly 50% of new infections in Europe - and up to 60% in Italy - detected at an advanced stage. Dermatovenereologists are key in early detection, as over 90% of people living with HIV show at least one HIV-related dermatologic condition before diagnosis. Thus, dermatovenereology services are well-positioned to promote routine HIV testing and prevention. Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method but is unevenly implemented across Europe. In Italy, PrEP is mostly prescribed by infectious disease specialists, except at a pioneering sexually transmitted infections (STI) center in Florence where dermatovenereologists can also prescribe it. Expanding this prescribing authority nationwide could improve access and prevention efforts among underserved populations. Integrating PrEP into dermatovenereology would enhance the continuum of care by linking STI screening, treatment, counseling, and HIV prevention, supporting UNAIDS' goal of ending AIDS by 2030. This narrative review summarizes key studies leading to PrEP approval, outlines approved administration methods for at-risk groups, discusses potential side effects, and highlights emerging therapeutic options under regulatory review (such as long-acting PrEP). It aims to equip dermatovenereologists with all the necessary tools to prescribe and manage PrEP effectively during follow-up.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA expression in vulvar lichen sclerosus keratinocytes and fibroblasts: further evidence and possible pathogenetic implications from an observational study.","authors":"Alessandro Borghi, Fernanda Martini, Lucilla D'Abundo, Cristian Bassi, Lucia Oton Gonzalez, Lucrezia Pacetti, Massimo Negrini, Monica Corazza","doi":"10.23736/S2784-8671.26.08591-9","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08591-9","url":null,"abstract":"<p><strong>Background: </strong>It seems established that genetic and epigenetic determinants drive the multifactorial pathogenic processes in vulvar lichen sclerosus (VLS). Aberrant expression of microRNAs (miRNAs) has been observed in a few studies suggesting their potential involvement. Our aim was to assess the expression of miRNAs both in VLS and in healthy keratinocytes and fibroblasts cultured separately.</p><p><strong>Methods: </strong>In this observational study, five VLS and five healthy skin tissue specimens were used to derive independent keratinocyte and fibroblast cultures. Total RNA, including miRNA, was isolated from cells, quantified and used to prepare a miRNA library. The quality and quantity of miRNA libraries were analyzed and sequenced. Differentially expressed miRNAs have been identified using DESeq2 bioconductor package.</p><p><strong>Results: </strong>The differential analysis led to the identification of 171 and 111 microRNAs with an expression difference of at least 1.5-fold between VLS and healthy samples, in keratinocytes and fibroblasts, respectively. More than 80% of the 111 microRNAs identified as differentially expressed in fibroblasts were also found to be differentially expressed in keratinocytes. Several dysregulated miRNAs are involved in inflammation and fibrotic processes, namely miR-10a-5p and 3p, miR-143-3p and 5p, miR-181a-5p and 3p, miR-181b-5p and 3p, miR-21-3p, miR-146b-5p and miR-29c.</p><p><strong>Conclusions: </strong>Our results showed a clear separation of VLS keratinocytes and fibroblasts from healthy cells in terms of miRNA expression. It is noteworthy that the most dysregulated miRNAs are implicated in inflammatory and fibrotic pathways. It is conceivable that miRNA expression is functional in regulating pathogenetic mechanisms of LS.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scabies: permethrin resistance and role of ivermectin. Results of an Italian consensus.","authors":"Laura Atzori, Riccardo Balestri, Andrea Bassi, Carlo Mazzatenta, Giuseppe Micali, Manuela Papini, Stefano Ramoni, Gaetano Scanni, Stefano Veraldi","doi":"10.23736/S2784-8671.26.08568-3","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08568-3","url":null,"abstract":"<p><p>Resistance to permethrin in patients with scabies emerged in recent years both in Italy and in the rest of Europe. A panel of nine Italian dermatologists with expertise in scabies was convened to address 23 questions regarding scabies therapy. Only agreement/disagreement responses were accepted. A unanimous conclusion emerged: permethrin should no longer be considered as first-line therapy for scabies in Italy. Benzyl benzoate was considered a reasonable alternative by two-thirds of the experts, although concentration and optimal formulation remain unclear and warrant further investigation. Full agreement was reached about ivermectin as first-line therapy. Ivermectin should be considered as the therapy of choice in patients with scabies.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italian interim analysis of NISSO: long-term sonidegib safety in locally advanced basal cell carcinoma.","authors":"Paolo A Ascierto, Ketty Peris, Maria C Fargnoli, Paolo Bossi, Vincenzo DE Giorgi, Lisa Licitra, Paola Savoia, Michele Guida, Francesco Spagnolo, Federica DE Galitiis, Ignazio Stanganelli, Loredana Romano, Serena Martelli, Ramon Arntz, Massimiliano Scalvenzi","doi":"10.23736/S2784-8671.26.08545-2","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08545-2","url":null,"abstract":"<p><strong>Background: </strong>Following the pivotal Phase II BOLT trial, sonidegib was approved by EMA to treat laBCC in patients not amenable to surgery or radiotherapy.</p><p><strong>Methods: </strong>The NISSO study (NCT04066504) is a non-interventional, multinational, multi-center, long-term, post-authorization, real-world safety study. Patients with laBCC were treated with sonidegib 200 mg orally once-daily and followed for 3 years according to the Prescribing Information.</p><p><strong>Results: </strong>Ninety-three patients were enrolled at 12 Italian centers with a median age of 79. The median exposure to sonidegib exposure was 8.9 months. At the time of the analysis, treatment ended in 65.6% patients, mainly due to patient/guardian decision, treatment success and physician decision. Most patients (78.5%) experienced at least 1 treatment-emergent adverse event (TEAE) including muscle spasms (39.8%), dysgeusia (32.3%), fatigue (21.5%); all of them decreased substantially after 3 months. Most TEAEs were Grade 1 and led to treatment discontinuation in 12.9%, while serious drug-related TEAEs were reported in 2.1% of patients. The Italian interim analysis shows a better real-world safety profile than could be expected based on the pivotal BOLT trial. Most patients experienced the onset of common AEs after 3 months.</p><p><strong>Conclusions: </strong>All the above supports the use of sonidegib as a manageable first-line systemic treatment in patients with laBCC.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of picosecond Nd:YAG 1064 nm laser in melasma treatment: a real-world retrospective analysis.","authors":"Thanh T Lê, Anh V Lê, Hưng Q Tạ, Thảo P Nguyễn, Alessandra Zevini, Daniela Martinelli, Riccardo Barini","doi":"10.23736/S2784-8671.26.08646-9","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08646-9","url":null,"abstract":"<p><strong>Background: </strong>Melasma is a challenging hyperpigmentation disorder, especially prevalent in individuals with darker skin tones. Traditional treatments, like hydroquinone and chemical peels, have limitations due to high recurrence rates and post-inflammatory hyperpigmentation (PIH) risk. Picosecond lasers have emerged as promising alternatives for treating melasma in patients with Fitzpatrick skin types III-IV. This study aims to evaluate the efficacy and safety of the 1064 nm Nd:YAG picosecond laser for melasma in a Vietnamese population.</p><p><strong>Methods: </strong>This retrospective study analyzed 29 female patients with mild to very severe melasma treated using a 1064 nm Nd:YAG picosecond laser. Each patient received an initial toning procedure followed by a fractional treatment, across three sessions at four-week intervals. Outcome measures included MASI (Melasma Area and Severity Index), MELASQoL (Melasma Quality of Life), VISIA imaging and colorimetric assessments. Follow-up visits were conducted at 4, 8, and 12 weeks after the first treatment.</p><p><strong>Results: </strong>Significant improvements were observed in MASI, MELASQoL, and pigmentation indices (L* and b*). VISIA analysis demonstrated significant reduction in superficial spots and brown spots, along with improvements in skin texture and wrinkles. Mild side effects were reported in 51.7% of patients, primarily erythema, which resolved spontaneously. No cases of PIH were documented.</p><p><strong>Conclusions: </strong>The 1064 nm Nd:YAG picosecond laser is an effective and safe treatment option for melasma in patients with Fitzpatrick skin types III-IV. Its ability to target melanin while minimizing thermal damage makes it particularly suitable for darker phototypes. Quantitative VISIA analysis supported treatment efficacy and revealed additional skin rejuvenation benefits. Further studies are required to assess long-term outcomes and recurrence rates.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Azithromycin therapy for papulo-pustular rosacea: efficacy and safety of a novel modified regimen.","authors":"Caterina M Giorgio, Eugenia V DI Brizzi, Gaetano Licata, Elisabetta Fulgione, Giuseppe Argenziano, Graziella Babino","doi":"10.23736/S2784-8671.26.08558-0","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08558-0","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of outcomes and satisfaction with tirbanibulin in actinic keratosis: a multicenter real-world study.","authors":"Andrea Carugno, Gianluca Nazzaro, Lisa Argnani, Francesco Bellinato, Elena Zappia, Maria V Masala, Giacomo Dal Bello, Mario Valenti, Giampaolo Addari, Giulia Ciccarese, Manfredo Bruni, Emanuele Trovato, Giovanni Paolino, Riccardo Balestri, Andrea D'Arino, Cristina Magnoni, Elisa Zavattaro, Giulia Toni, Roberta Giuffrida, Alice Verdelli, Stefano Caccavale, Alessia Villani, Serena Giacalone, Sebastiano Recalcati, Stefania Barruscotti, Stefano Bighetti, Luca Bettolini, Giovanni Fiorillo, Lerica Germi, Stefano Fazio, Carmen Cantisani, Vincenzo Maione, Salvatore D Infusino, Laura Eibenschutz, Alice Cesari, Martina Dragotto, Grazia B Zolo, Anna E Verzì, Paola Savoia, Iris Zalaudek, Elia Sala, Enzo Errichetti, Santo R Mercuri, Maria Esposito, Caterina Foti, Laura Atzori, Marco Ardigò, Francesco Lacarrubba, Maria Concetta Fargnoli, Pietro Danese, Simone Ribero, Paolo Gisondi, Angelo V Marzano, Nicola Zerbinati","doi":"10.23736/S2784-8671.26.08682-2","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08682-2","url":null,"abstract":"<p><strong>Background: </strong>Tirbanibulin 1% ointment is a short-course field therapy for actinic keratosis (AK). Real-world data on predictors of response, tolerability, and satisfaction may support patient selection and counselling. The aim was to evaluate effectiveness and tolerability in a large multicenter cohort, identify predictors of high clinical clearance and local skin reactions (LSRs), and describe patient and physician satisfaction.</p><p><strong>Methods: </strong>This retrospective observational real-life study (33 Italian dermatology centers) included 679 patients. Clinical response was classified as complete (100%), good (75-99%), moderate (50-74%), or <50% clearance; high clearance was defined as ≥75%. AK severity was assessed using AK Area and Severity Index (AKASI). LSRs were graded 0-4, and a total score was calculated. Satisfaction was rated 0-4 (scores 3-4 indicated high satisfaction.) Multivariable logistic regression identified predictors of high clearance, erythema, and vesiculation/pustulation.</p><p><strong>Results: </strong>Patients were predominantly male (70.8%), mean age 74.9±9.7 years; 77.6% were AK-experienced. All patients completed treatment. High clearance occurred in 69.7% and was greater in AK-naïve patients (78.3% vs. 67.1%, P<0.001). Mean AKASI decrease was 63.2%; photodamage improvement was 30.5%. Tolerability was favorable (mean LSR score 0.65±0.90); 11.9% of LSRs were ≥3, with no grade 4 vesiculation/ulceration occurring. Lower Olsen grade independently predicted high clearance. Female sex and age ≥75 years were associated with higher odds of selected LSRs. High satisfaction was reported by 79.4% of patients and 83.1% of physicians.</p><p><strong>Conclusions: </strong>Tirbanibulin 1% achieved high clearance with favorable tolerability and satisfaction, supporting its use in individualized management of field cancerization.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.","authors":"Paolo Gisondi, Martina Burlando, Maria Esposito, Matteo Megna, Diego Orsini, Simone Ribero, Emanuele Trovato, Clara DE Simone","doi":"10.23736/S2784-8671.26.08674-3","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08674-3","url":null,"abstract":"<p><strong>Background: </strong>The fixed-dose combination of calcipotriol and betamethasone dipropionate (Cal/BDP) is an established topical psoriasis treatment. The cream formulation of Cal/BDP has been found effective and well-tolerated for the treatment of mild-to-moderate disease, with high levels of patient satisfaction. The aim of this consensus document is to guide optimal real-life use of Cal/BDP cream in patients with psoriasis.</p><p><strong>Methods: </strong>Eight hospital-based dermatologists, with long-standing experience in psoriasis treatment, developed a consensus document on three topics (therapeutic protocols and schedules; high-impact areas; and treatment adherence) regarding the use of Cal/BDP cream in clinical practice. A modified Delphi process was used to achieve consensus among panel members. Statements with treatment recommendations, based on the experts' opinions and experience, as well as an analysis of relevant published data, were elaborated on and discussed during two meetings occurring two months apart. Full agreement among panel members was obtained after two online Delphi rounds.</p><p><strong>Results: </strong>As seen in clinical trials, Cal/BDP cream monotherapy has proved beneficial in the treatment of mild to moderate plaque psoriasis. However, it can also be used as an adjunct to systemic/biologic drug treatment or as long-term maintenance therapy. Cal/BDP cream also plays an important role in the treatment of psoriasis on high-impact sites (including the scalp, peripheral facial areas, skin folds and palmoplantar areas) with treatment schedules varying according to disease severity and area involved. Due to its vehicle, treatment with Cal/BDP cream is associated with high levels of treatment convenience and patient acceptability, positively impacting adherence.</p><p><strong>Conclusions: </strong>Cal/BDP cream can be used safely and effectively for the treatment of psoriasis in a range of clinical presentations. Its favorable cosmetic characteristics contribute to treatment success by enhancing patient adherence. Studies on the long-term use of Cal/BDP cream as a maintenance therapy are needed.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necrotizing leukocytoclastic vasculitis induced by alpelisib.","authors":"Sebastiano Posenato, Lucrezia Pacetti, Aikaterini Kalpaktsoglou, Alessandro Borghi","doi":"10.23736/S2784-8671.26.08495-1","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08495-1","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary cutaneous lymphomas in children: a single-center retrospective analysis and narrative review of the literature.","authors":"Luca Rapparini, Margherita Ricci, Corrado Zengarini, Alba Guglielmo, Gregorio Baruffaldi, Michelangelo LA Placa, Iria Neri, Alessandro Pileri","doi":"10.23736/S2784-8671.26.08555-5","DOIUrl":"10.23736/S2784-8671.26.08555-5","url":null,"abstract":"<p><strong>Background: </strong>Primary cutaneous lymphomas (PCLs) are uncommon in children, with mycosis fungoides (MF), lymphomatoid papulosis (LyP), and primary cutaneous small/medium CD4+ T-cell lymphoproliferative disorder (PCSM-TCLPD) representing the most frequent entities. Due to their rarity, available data derive mainly from case reports and small series, and diagnostic delays are frequent. This study aimed to describe the clinical, histopathological, and therapeutic features of pediatric PCLs in a single Italian referral centre and compare them with the literature evidence.</p><p><strong>Methods: </strong>We conducted a single-center, retrospective observational study including patients aged ≤16 years with a histologically confirmed diagnosis of PCLs, followed for at least six months at the Dermatology Unit of the University Hospital of Bologna between 2002 and 2024. Clinical, histological, therapeutic, and follow-up data were collected and analyzed.</p><p><strong>Results: </strong>Among 354 PCL patients, 10 pediatric cases were identified: six MF, three LyP, and one PCSM-TCLPD. The mean age at diagnosis was 9.1 years. MF cases were mostly early-stage (IA, 5/6), with folliculotropic (67%), hypopigmented (50%), and classic (50%) variants; all were treated with topical corticosteroids and/or PUVA, with good long-term outcomes (67% complete remission). LyP patients presented at younger ages (mean 5.7 years) with type A (N.=2) and D (N.=1) subtypes; all achieved complete remission despite recurrences, one requiring methotrexate. The single PCSM-TCLPD case was cured with surgical excision. After a mean follow-up of 8.2 years, all patients were alive, most disease-free.</p><p><strong>Conclusions: </strong>Pediatric PCLs are rare but generally indolent, with an excellent prognosis. However, their clinical heterogeneity and diagnostic delay highlight the importance of early biopsy, integrated clinicopathological assessment, and long-term follow-up. Multicenter studies are needed to establish tailored treatment algorithms for children.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"388-395"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}